Approved Diagnostic Molecule in Preclinical Studies to Evaluate Potential in ALS

Approved Diagnostic Molecule in Preclinical Studies to Evaluate Potential in ALS

294920

Approved Diagnostic Molecule in Preclinical Studies to Evaluate Potential in ALS

Researchers at the University of Queensland in Australia have begun preclinical studies of macimorelin, Aeterna Zentaris’ approved oral diagnostic, as a potential treatment for amyotrophic lateral sclerosis (ALS). The preclinical development program, led by Frederik Steyn, PhD, is part of a recent agreement between university researchers and Aeterna that provides the latter exclusive right to create a licensing agreement for macimorelin’s commercial use for the treatment of ALS. “The start of the preclinical phase represents a…

You must be logged in to read/download the full post.